ArticleDrug testing and analysis2026
Investigations Into the Metabolism and Elimination of Flmodafinil and Fladrafinil for Sports Drug Testing Purposes.
Article in Drug testing and analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Flmodafinil (CRL-40,940; 2-[bis(4-fluorophenyl)methylsulfinyl]acetamide) and fladrafinil (CRL-40,941; 2-[bis(4-fluorophenyl)methylsulfinyl]-N-hydroxyacetamide) are structural analogs of modafinil. Their reported stimulating effects on the central nervous system have contributed to an increasing popularity outside the medical field, particularly for the enhancement of cognitive performance. In recent years, there has been a notable increase in interest within the sporting community regarding substances such as modafinil. Flmodafinil and fladrafinil are subjects of class "S6 stimulants" of the World Anti-Doping Agency (WADA) Prohibited List, and therefore prohibited in-competition. In this study, the elimination profiles of flmodafinil, fladrafinil, and their metabolites in urine and blood were investigated. Six volunteers ingested 20 mg of either flmodafinil or fladrafinil. Urine and blood (DBS) samples were analyzed by means of LC-HRMS, where limits of detection between 0.2 and 4 ng/mL were accomplished. After ingestion of flmodafinil, the metabolites flmodafinil acid and flmodafinil sulfone were detected. Since fladrafinil acts as a prodrug for flmodafinil, these metabolites were likewise detected after ingestion of fladrafinil. It was found that urinary maximum concentrations ranged from 191 to 891 ng/mL for flmodafinil and from 52 to 111 ng/mL for fladrafinil. The maximum concentrations in blood ranged from 45 to 98 ng/mL for flmodafinil and from 11 to 35 ng/mL for fladrafinil. When fladrafinil is administered, a slight offset can be seen until the maximum concentration of flmodafinil is reached, related to the conversion of the prodrug fladrafinil to flmodafinil. In consideration of the relatively long detection windows of both the intact drugs and their metabolites, careful result interpretation is indicated in case of an AAF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.